- Erlotinib in treatment of NSCLC focusing on patients without EGFR mutation and on combination of erlotinib with bevacizumab2017 | Faculty of Medicine in Pilsen
- Erlotinib in Treatment of NSCLC (Focusing on Patients without EGFR Mutation and on Combination of Erlotinib with Bevacizumab)2017 | Faculty of Medicine in Pilsen
- Erlotinib in the first line treatment of the metastatic non-small cell lung cancer2018 | Third Faculty of Medicine
- KRAS (G12S) mutation in a patient with NSCLC treated with erlotinib – a case report2013 | Faculty of Medicine in Pilsen
- Adverse skin reaction to erlotinib therapy2010 | Central Library of Charles University
- Adverse skin reaction to erlotinib therapy2010 | Faculty of Medicine in Pilsen
- Effect of clinical parameters on second- and third-line erlotinib treatment of EGFR wild type patients with advanced NSCLC2019 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Central Library of Charles University, Second Faculty of Medicine
- Erlotinib in the treatment of advanced non-small cell lung cancer - present experience and results in the Czech Repuiblic2018 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Second Faculty of Medicine
- Thyroid transcription factor 1 and p63 expression is associated with survival outcome in patients with non-small cell lung cancer treated with erlotinib2020 | Faculty of Medicine in Pilsen
- Efficacy of erlotinib in subsequent lines of non-small cell lung cancer therapy2018 | Third Faculty of Medicine
- Impact of EGFR and KRAS mutations on survival prognosis of NSCLC patients treated with tyrosine-kinase inhibitors: Comparison of gefitinib and erlotinib.2009 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial2007 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- Impact of EGFR and KRAS mutations on survival prognosis of NSCLC patients treated with tyrosine-kinase inhibitors: Comparison of gefitinib and erlotinib.2009 | Central Library of Charles University
- Impact of EGFR and KRAS mutations on survival prognosis of NSCLC patients treated with tyrosine-kinase inhibitors: Comparison of gefitinib and erlotinib.2009 | Faculty of Medicine in Pilsen
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. OSI-774-302Publication without faculty affiliation
- Follow-up of expensive pneumo-oncological treatment of advanced non-small cell lung cancer in the I. line of the TULUNG register in the Czech Republic2013 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Central Library of Charles University
- Erlotinib in the treatment of advanced squamous cell NSCLC2013 | Faculty of Medicine in Pilsen, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Second-line treatment of advanced NSCLC: Comparison of efficacy of erlotinib and chemotherapy2013 | Faculty of Medicine in Pilsen
- Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice2013 | Faculty of Medicine in Pilsen
- Clinical registry TULUNG2012 | Faculty of Medicine in Pilsen, Third Faculty of Medicine
- Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report2014 | Faculty of Medicine in Pilsen
- Serum Concentration of Erlotinib and its Correlation with Outcome and Toxicity in Patients with Advanced-stage NSCLC2017 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Faculty of Science
- Tarceva Clinical Registry2010 | Faculty of Medicine in Pilsen, Third Faculty of Medicine
- Information on clinical registry Tarceva2010 | Faculty of Medicine in Pilsen, Third Faculty of Medicine, First Faculty of Medicine
- Extraordinary response to erlotinib therapy in a patient with lung adenocarcinoma exhibiting KRAS mutation and EGFR amplification2011 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- Pemetrexed Versus Erlotinib in the Second-line Treatment of Patients with Advanced-stage Non-squamous NSCLC Harboring Wild-type EGFR Gene2016 | Faculty of Medicine in Pilsen, Faculty of Science
- Predictive Role of CEA and CYFRA 21-1 in Patients with Advanced-stage NSCLC Treated with Erlotinib2014 | Faculty of Medicine in Pilsen
- Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib2016 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Faculty of Science
- Sequential Treatment of Advanced-stage Lung Adenocarcinoma Harboring Wild-type EGFR Gene: Second-line Pemetrexed Followed by Third-line Erlotinib versus the Reverse Sequence2013 | Faculty of Medicine in Pilsen
- Skin adverse reactions from erlotinib2007 | Faculty of Medicine in Pilsen, Central Library of Charles University